Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase I study.
Michael J. Mauro
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Pfizer; Pfizer
Neil P. Shah
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD; Bristol-Myers Squibb
Dale Bixby
Consultant or Advisory Role - ARIAD
Ian Flinn
Research Funding - ARIAD
Thomas O'Hare
No relevant relationships to disclose
Simin Hu
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Research Funding - ARIAD
Christopher D. Turner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Brian J. Druker
Consultant or Advisory Role - MolecularMD
Stock Ownership - MolecularMD
Research Funding - ARIAD
Michael W. N. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Gilead Sciences; Novartis
Moshe Talpaz
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD